Several psychedelic drugs are touted as effective treatments for drug and alcohol abuse. But psilocybin combined with therapy is emerging as the most effective.

Numinus announces enrolling the first volunteer patient as it hosts a MAPS clinical trial for an MDMA-assisted treatment for PTSD.

Albert Labs announces the filing of a provisional patent application for the production of Psilocybe mycelia and other fungi.

Enveric Biosciences announces that it has expanded on its psychedelic drug R&D pipeline along with filing a new patent application.

After strong preclinical testing results, Cybin is looking to advance CYB003 into a Plase 1/2a clinical trial, estimated for mid-2022.

– FDA cleared MindMed’s Investigational New Drug (IND) application for Phase 2b dose optimization trial of MM-120 – – Progressed development programs for all three lead product candidates – – Cash balance of $133.5 million at year end 2021 – – Company to host earnings conference call today at 8:30…

Mydecine reports conditional approval to commence a Phase IIb study on smoking cessation, in partnership with Johns Hopkins University.

Novamind announces plans to expand group therapy within its clinical therapy model.

For 50 years Western governments have relentlessly undermined the mental health of their citizens while also criminalizing the only effective drugs for treating mental health.

Pharmather reports positive tolerability and dose-finding results in its clinical trial of a ketamine-based drug for Parkinson’s disease as it prepares for a Phase III trial.